First launches for Servier's Valdoxan
This article was originally published in Scrip
Servier is introducing its melatonergic antidepressant, Valdoxan (agomelatine) in the UK, one of its first major launches worldwide. It has also been launched recently in Ukraine, Russia and Germany, and is being co-developed for the US with Novartis.
You may also be interested in...
France’s fledgling biotech Dynacure has pulled together a series C funding round to support its ongoing Phase I/II study of an antisense molecule for an ultrarare myopathy.
A transatlantic initiative is screening a US library of 15,000 pharmacologically active compounds for anti-COVID-19 activity, using artificial intelligence technologies.